Literature DB >> 17709725

Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.

Sam M Wiseman1, Obi L Griffith, Shaun Deen, Ashish Rajput, Hamid Masoudi, Blake Gilks, Lynn Goldstein, Allen Gown, Steven J M Jones.   

Abstract

HYPOTHESIS: A change in tumor expression profile will be observed during the transformation of differentiated into anaplastic thyroid carcinoma.
DESIGN: Cohort study.
SETTING: Population-based sample (British Columbia). PATIENTS: Sequential archival cases of anaplastic thyroid cancer with an adjacent associated differentiated thyroid cancer focus, and with available paraffin blocks, that had been diagnosed and treated in British Columbia during a 20-year period (12 cases; January 1, 1984, through December 31, 2004) were identified through the provincial tumor registry for tissue microarray construction. MAIN OUTCOME MEASURE: Significant associations between marker staining and tumor pathologic diagnosis (differentiated vs anaplastic) were determined with contingency table and marginal homogeneity tests. A classifier algorithm was also used to identify useful and important molecular classifiers.
RESULTS: Overall, there were 3 up-regulated and 5 down-regulated markers when comparing the anaplastic carcinoma with associated differentiated thyroid cancers. Contingency table statistics identified 5 markers (thyroglobulin, Bcl-2, MIB-1, E-cadherin, and p53) to be significantly differentially expressed by the anaplastic and differentiated tumor foci. These 5 markers and 3 others (beta-catenin, topoisomerase II-alpha, and vascular endothelial growth factor) were significant when evaluated using the marginal homogeneity test. Clustering and classification analysis based on these same 8 markers readily separated differentiated and anaplastic thyroid tumors with a high degree of accuracy.
CONCLUSION: The markers we observed to change during thyroid tumor progression may not only show promise as molecular diagnostic or prognostic tools but also warrant further study as potential targets for treatment of disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709725     DOI: 10.1001/archsurg.142.8.717

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  22 in total

1.  Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.

Authors:  Akira Yoshida; Kiminori Sugino; Iwao Sugitani; Akira Miyauchi
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

2.  Expression of p63 and Bcl-2 in Malignant Thyroid Tumors and their Correlation with other Diagnostic Immunocytochemical Markers.

Authors:  Ashumi Gupta; Shyama Jain; Nita Khurana; Arun Kumar Kakar
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 3.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

Review 4.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

5.  Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Authors:  Matthew A Nehs; Carmelo Nucera; Sushruta S Nagarkatti; Peter M Sadow; Dieter Morales-Garcia; Richard A Hodin; Sareh Parangi
Journal:  Endocrinology       Date:  2011-12-27       Impact factor: 4.736

Review 6.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 7.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

8.  Proceedings of the 2018 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Vinicius Carreira; Caralyn S Labriola; Debabrata Mahapatra; Sean R McKeag; Matthias Rinke; Cynthia Shackelford; Bhanu Singh; Ashley Talley; Shannon M Wallace; Lyn M Wancket; Cynthia J Willson
Journal:  Toxicol Pathol       Date:  2018-10-03       Impact factor: 1.902

Review 9.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

10.  Expression of hedgehog signalling pathway in anaplastic thyroid cancer.

Authors:  Ulrike Hinterseher; Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Detlef K Bartsch; Stefan Hauptmann; Brandon H Greene; Volker Fendrich; Sebastian Hoffmann
Journal:  Endocrine       Date:  2013-07-17       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.